Wrestling with set­backs, Cel­gene adds $65M dis­cov­ery al­liance with Evotec to beef up on new can­cer drugs

Cel­gene has added a $65 mil­lion up­front por­tion of on­col­o­gy dis­cov­ery work with Evotec, 18 months af­ter the two com­pa­nies al­lied on neu­rode­gen­er­a­tion work. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER